Literature DB >> 29201790

Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh.

Mamun Al Mahtab1, Sheikh Mn Alam1, Ahmed L Moben2, Ruksana Raihan3, Mohammad A Alam4, Mohammad A Rahim5, Mohammad H Uddin6, Sheikh Mohammad Fazle Akbar7.   

Abstract

INTRODUCTION: Decompensated cirrhosis is associated with significantly high mortality resulting from hepatic failure, and liver transplantation seems to be the only viable indication for its management. The objective of this study is to assess if granulocyte colony-stimulating factor (G-CSF), a stimulatory of stem cell in vivo, may be of any benefit for patients with decompensated cirrhosis of liver.
MATERIALS AND METHODS: Seventeen consecutive patients with decompensated cirrhosis of liver were recruited in this prospective study. They received injection of G-CSF (30 IU) over a period of 6 weeks (12 injections) in addition to standard of care.
RESULTS: Patients were followed up at the end of treatment and at 12 weeks of treatment. Treatment was well tolerated, and no significant adverse event was recorded in any patient. Fifteen out of 17 (88%) patients were alive at last follow-up. Although serum bilirubin, albumin, and prothrombin time improved in some patients, statistically significant improvement of Child-Pugh score could not be documented.
CONCLUSION: The study establishes the safety of G-CSF therapy in patients with decompensated cirrhosis of liver. Besides, such therapy may also have survival benefit, although long-term follow-up is needed to assess its real utility in clinical perspectives.How to cite this article: Al Mahtab M, Alam SMN, Moben AL, Raihan R, Alam MA, Rahim MA, Uddin MH, Akbar SMF. Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh. Euroasian J Hepato-Gastroenterol 2017;7(1):113-115.

Entities:  

Keywords:  Decompensated liver cirrhosis; Granulocyte colony stimulating factor; Prognosis; Stem cell; Therapy.

Year:  2017        PMID: 29201790      PMCID: PMC5663792          DOI: 10.5005/jp-joumals-10018-1229

Source DB:  PubMed          Journal:  Euroasian J Hepatogastroenterol        ISSN: 2231-5047


  4 in total

1.  Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.

Authors:  Chandan Kumar Kedarisetty; Lovkesh Anand; Ankit Bhardwaj; Ajeet Singh Bhadoria; Guresh Kumar; Ashish Kumar Vyas; Paul David; Nirupama Trehanpati; Archana Rastogi; Chhagan Bihari; Rakhi Maiwall; Hitendra Kumar Garg; Chitranshu Vashishtha; Manoj Kumar; Vikram Bhatia; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2015-03-04       Impact factor: 22.682

2.  Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure.

Authors:  Hitendra Garg; Ashish Kumar; Vishal Garg; Praveen Sharma; Barjesh Chander Sharma; Shiv Kumar Sarin
Journal:  Dig Liver Dis       Date:  2011-10-05       Impact factor: 4.088

3.  Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluation.

Authors:  Silvia Gaia; Antonella Olivero; Antonina Smedile; Marco Ruella; Maria Lorena Abate; Maurizio Fadda; Emanuela Rolle; Paola Omedè; Paola Bondesan; Roberto Passera; Alessandra Risso; Manuela Aragno; Alfredo Marzano; Alessia Ciancio; Mario Rizzetto; Corrado Tarella
Journal:  Hepatol Int       Date:  2013-10-11       Impact factor: 6.047

4.  Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure.

Authors:  Xue-Zhang Duan; Fang-Fang Liu; Jing-Jing Tong; Hao-Zhen Yang; Jing Chen; Xiao-Yan Liu; Yuan-Li Mao; Shao-Jie Xin; Jin-Hua Hu
Journal:  World J Gastroenterol       Date:  2013-02-21       Impact factor: 5.742

  4 in total
  5 in total

1.  Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country.

Authors:  Mamun Al Mahtab; Sheikh Mf Akbar; Masuda Begum; Md A Islam; Md A Rahim; Sheikh M Noor-E-Alam; Md A Alam; Faiz A Khondaker; Ahmed L Moben; Masuda Mohsena; Md Sakirul I Khan; Md Z Huq; Swati Munshi; Ashraful Hoque; Sheikh A Haque
Journal:  Euroasian J Hepatogastroenterol       Date:  2019-02-01

2.  Effect of Granulocyte Colony-stimulating Factor and Erythropoietin on Patients with Acute-on-chronic Liver Failure.

Authors:  Md Nazmul Haque; Mamun Al-Mahtab; Dulal C Das; Noor-E-Alam Sheikh Mohammad; Ayub A Mamun; Md Sakirul I Khan; Sheikh Mf Akbar; Salimur Rahman
Journal:  Euroasian J Hepatogastroenterol       Date:  2020 Jul-Dec

3.  Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure.

Authors:  Sharker M S Hossain; Mamun A Mahtab; Dulal C Das; Sheikh M Noor-E-Alam; Ayub A Mamun; Md Sakirul I Khan; Sheikh M F Akbar; Md Zakiur Rahman; Salimur Rahman
Journal:  J Family Med Prim Care       Date:  2021-07-30

4.  Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure.

Authors:  Debraj Malakar; Mamun A Mahtab; Abul H Manik; Sheikh M Noor E Alam; Dulal C Das; Ayub A Mamun; Md Sakirul Islam Khan; Zakiur Rahman; Salimur Rahman; Sheikh Mohammad Fazle Akbar
Journal:  J Family Med Prim Care       Date:  2021-07-02

5.  Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure.

Authors:  Abul H Manik; Debraj Malakar; Sheikh M Noor-E-Alam; Mamun A Mahtab; Dulal C Das; Ayub A Mamun; Sakirul Khan; Mohammad Fazle Akbar; Zakiur Rahman; Salimur Rahman
Journal:  J Family Med Prim Care       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.